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Background: Recent epidemiological studies have shown that growing up on a traditional farm provides
protection from the development of allergic disorders such as hay fever and allergic asthma. We present
experimental evidence that substances providing protection from the development of allergic diseases can
be extracted from dust collected in stables of animal farms.
Methods: Stable dust was collected from 30 randomly selected farms located in rural regions of the Alps
(Austria, Germany and Switzerland). The dust was homogenised with glass beads and extracted with
physiological sodium chloride solution. This extract was used to modulate immune response in a well
established mouse model of allergic asthma.
Results: Treatment of mice by inhalation of stable dust extract during sensitisation to ovalbumin inhibited
the development of airway hyperresponsiveness and airway eosinophilia upon challenge, as well as the
production of interleukin 5 by splenocytes and of antigen specific IgG1 and IgE. Dust extract also
suppressed the generation of human dendritic cells in vitro. The biological activity of the dust extract was
not exclusively mediated by lipopolysaccharide.
Conclusions: Stable dust from animal farms contains strong immune modulating substances. These
substances can interfere with the development of both cellular and humoral immunity against allergens,
thus suppressing allergen sensitisation, airway inflammation, and airway hyperresponsiveness in a murine
model of allergic asthma.
O
ne explanation for the increase in allergic diseases
during the last 30 years originates from the ‘‘hygiene
hypothesis’’ which proposes that increases in the
prevalence of allergic disorders are linked to changes in the
microbial burden to which children are exposed in early life.1–4
Epidemiological studies have recently shown that growing up
on a traditional animal farm can protect from sensitisation to
allergens and the development of asthma and hay fever. The
exposure of infants to the environment of stables during
the first year of life seems to be crucial for this protection. In the
search for pathogen derived factors which inhibit the develop-
ment of allergen sensitisation, many studies have concentrated
on lipopolysaccharide (LPS), which can induce allergy protec-
tive Th1 type immune responses in animal experiments.5–7
Interestingly, LPS levels in dust from mattresses of children
were inversely related to the frequency of atopic sensitisation
and atopic asthma, and overall endotoxin levels were
significantly higher in dust from farming than from non-
farming households.2 A recent study showed that, in addition
to endotoxin, other microbial components such as peptidogly-
cans were associated with a reduction in non-atopic asthma
symptoms.4
In animal models of allergen induced asthma, LPS
treatment led to Th1 dominated immune responses.7 8
Given systemically before sensitisation, LPS reduced both
the production of allergen specific IgE and numbers of
eosinophils in the bronchial mucosa, demonstrating that the
Th2 response normally associated with allergic sensitisation
in mice was inhibited. In contrast to these animal models,
LPS activation of peripheral blood mononuclear cells in
children, who themselves had been exposed to high amounts
of endotoxin levels in early childhood, seemed to lead to
immune tolerance to LPS.2 This finding indicates that
downregulation rather than activation of the immune
response to bacterial pathogens is associated with protection
from allergy. These conflicting results suggest that LPS is
probably primarily a marker for microbial burden rather than
the principal molecule responsible for the protective effect of
the farm environment. It is possible that allergy protection
induced by the exposure to a farming environment is linked
to the activity of T regulatory cells (Treg) releasing
transforming growth factor b (TGF-b) and interleukin (IL)-
10 and suppressing both Th1 and Th2 immune responses.9 10
To date there has been no experimental confirmation for
the epidemiological observation that exposure to stable dust
reduces the risk for allergic diseases. A study was therefore
undertaken in which dust was collected from stables of
traditional farms, extracted with physiological sodium
chloride solution, and tested to determine whether inhalation
of this extract could modify allergic responses in a mouse
model of acute allergic asthma. The influence of the dust
extract on the generation of dendritic cells from human
monocytes was also determined in vitro.
METHODS
Collection of stable dust
A total of 30 farming households were selected, all located in
rural regions of the Alps where the previous field studies
were also conducted.1 2 Sediment dust from cattle and goat
stables was collected by scraping off all surfaces at a height of
Abbreviations: AHR, airway hyperresponsiveness; BAL,
bronchoalveolar lavage; IFN-c, interferon c; IL, interleukin; LPS,
lipopolysaccharide; PBS, phosphate buffered saline
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0.05–0.15 m (racks, tables, tools) with a metal spatula. From
each farm 100–200 g dust was collected and passed through a
conventional kitchen sieve. All dust samples were then
combined.
Extraction of stable dust
For homogenisation of the dust, 15 g of glass beads (0.4–
0.6 mm in diameter) were added to 10 g dust, double
distilled water was added to give a final volume of 70 ml,
and the sample was homogenised in a Braun MSK homo-
geniser (B Braun, Melsungen, Germany). Five samples
( = 50 g of dust) were combined and extracted with 0.9%
aqueous sodium chloride (NaCl) solution (total volume
5 litres) for 6 hours at 22 C˚ with continuous stirring. After
centrifugation the dust extract was dialysed against water
and then lyophilised.
Animals
Female BALB/c mice (Charles River, Sulzfeld, Germany) aged
7–8 weeks were used and acclimated to the animal facility for
14 days before the experiments. The animals had access to
food and water ad libitum. All experimental procedures were
approved by the animal ethics committee at Bezirksregierung
Arnsberg.
Sensitisation and airway challenge
Mice were sensitised by intraperitoneal injection of 20 mg
ovalbumin (OVA gradeV; Sigma, St Louis, MO, USA)
emulsified in 2.2 mg aluminum hydroxide (ImjectAlum;
Pierce, Rockford, IL, USA) in a total volume of 200 ml on
days 1 and 14. On days 28 and 38 mice were challenged via
the airways with 1% OVA aerosol for 20 minutes (fig 1) using
a PARI-Boy aerosol generator. Controls were injected with
aluminum hydroxide alone and challenged with PBS aerosol
(non-sensitised).
Treatment of animals with stable dust extract
Mice were treated with stable dust extract during the
sensitisation phase (fig 1). Extract was administered as
aerosol generated from a 10 mg/ml solution. For treatment,
the mice were placed in a plexiglass chamber (volume
11 litres) which was connected to a PARI-Boy Turbo jet
stream aerosol generator (PARI, Starnberg, Germany) and
allowed to inhale the aerosol for 20 minutes. Mice were
treated 14 times beginning on the day of the first OVA
injection and the last treatment 6 days before the second
OVA aerosol challenge (fig 1). Control groups were sensitised
as described above and treated 14 times with either
phosphate buffered saline (PBS) or 0.8 mg/ml E coli LPS
during the sensitization phase. The LPS concentration was
chosen to match the concentration in the dust extract
detected by Limulus amebocyte lysate assay. The E coli LPS
used in the study was purified at Forschungszentrum Borstel.
In stimulation assays with human mononuclear cells it is
highly biological active, and induces maximal tumour
necrosis factor (TNF)-a release at a concentration of 2 ng/
ml and maximal IL-10 release at 0.4 ng/ml.
Airway responsiveness
24 hours after the last aerosol challenge airway hyperrespon-
siveness (AHR) to methacholine aerosol (0, 6, 12, 25 and
50 mg/ml, Sigma) was evaluated in conscious unrestrained
mice using whole body plethysmography (Buxco Electronics)
by measuring the enhanced pause (Penh).11–13 Previous
studies have shown that the AHR to methacholine reaches
its maximum 24 hours after OVA challenge.12 Furthermore, it
has been shown that, in this experimental setting, AHR
assessed by Penh correlates closely with increases in airway
resistance in ventilated animals.12
In vitro cytokine production of mouse splenocytes
Spleens were harvested 3 days after the second aerosol
challenge. Single cell suspensions were prepared by mechan-
ical disruption and erythrocytes were lysed. Spleen cells were
then cultured at a concentration of 56106/ml in complete
tissue culture medium (CTCM) (RPMI 1640 with 10% fetal
calf serum (FCS), 2 mM L-glutamine, 100 U/ml penicillin,
100 mg/ml streptomycin, all from Biochrom, Berlin,
Germany). To stimulate specific cytokine production, OVA
was added to a final concentration of 50 mg/ml. After
48 hours of culture, supernatants were taken and stored at
–80 C˚ until analysis. Levels of IL-5 and IL-10 were assessed
using optEIA kits (BD Biosciences, Heidelberg, Germany)
according to the manufacturer’s instructions.
Bronchoalveolar lavage (BAL)
Three days after OVA challenge the lungs were lavaged via a
tracheal tube with 261 ml PBS and leucocytes in the lavage
fluid were counted. After centrifugation, BAL fluid was
frozen for further analysis. Cytospin slides of BAL cells were
stained with a fast staining procedure (HAEME-
Schnellfa¨rbung, Labor+Technik Eberhard Lehmann, Berlin,
Germany) according to the manufacturer’s instructions. The
percentages of eosinophils, lymphocytes, and macrophages in
BAL fluid samples were determined by light microscopy. At
least 300 cells per sample were differentiated by a blinded
investigator.
Measurement of OVA specific IgG1, IgG2a and IgE in
serum and BAL fluid
Blood was collected by tail vein puncture 2 days after the
second aerosol challenge. BAL fluid was collected as
described above. Levels of OVA specific IgG1, IgG2a and IgE
in serum or BAL fluid were determined by ELISA. Briefly,
sample wells of a Nunc maxisorb ELISA plate (Nunc,
Wiesbaden, Germany) were coated with 5 mg/ml OVA over-
night and then blocked with 1% bovine serum albumin. After
incubation with diluted samples, bound OVA specific
antibodies were detected with isotype specific antibodies,
rat anti-mouse IgG2a (clone R19-15) and rat anti-mouse IgG1
(clone X56), both conjugated to alkaline phosphatase or
biotinylated rat anti-mouse IgE (clone R35-72) (all from BD
Biosciences). The latter antibody was detected by horseradish
peroxidase conjugated extravidin (Sigma). In control experi-
ments isotype specific rat anti-mouse IgE antibody does not
cross react with IgG1 or IgG2a isotype. Serum levels of OVA
specific IgG1 and IgE were related to combined standard sera
generated in our laboratory and expressed as arbitrary units
per ml. Levels of OVA specific IgG2a in 1/10 diluted serum
were expressed as optical density measured at a wavelength
of 405 nm (OD405).
Day 0 14 28 38 39 41
Inhalation of dust extract 20 min
AR Analysis
OVA i.p.
OVA
aerosol
Figure 1 Design of in vivo experiments. OVA i.p. denotes systemic
immunisation with ovalbumin adsorbed in aluminum hydroxide. OVA
aerosol indicates challenges with 1% ovalbumin aerosol via the airways.
AR, airway responsiveness. Analysis indicates harvest of
bronchoalveolar lavage fluid cells, serum, and splenocytes for analysis.
Inhalation of stable dust 135
www.thoraxjnl.com
 group.bmj.com on July 10, 2013 - Published by thorax.bmj.comDownloaded from 
Generation of human dendritic cells in vitro
Human monocyte derived dendritic cells were generated
essentially as described elsewhere.14 Briefly, mononuclear
cells were isolated from the peripheral blood of healthy
volunteers by Ficoll-Paque density gradient centrifugation.
Monocytes were purified by centrifugal elutriation or
adherence to plastic for 2 hours at 37 C˚ each yielding similar
results. Purified monocytes were cultured at 37 C˚ in 5% CO2
for 7 days at 16106/ml in CTCM supplemented with 500 U/
ml recombinant human GM-CSF, 500 U/ml recombinant
human IL-4 (both from PeproTech, London, UK) and with or
without 25 mg/ml dust extract or 2 ng/ml LPS from E coli as a
matched control to the LPS content of dust extract. Every
other day 50% of the medium was replaced by fresh
prewarmed medium containing the same supplements. To
induce maturation, 250 ng/ml LPS were added on day 6 and
cells were incubated for another 24 hours.
Flow cytometric analysis
Flow cytometric analysis of monocyte and DC specific surface
antigens was performed on a FACSCalibur flow cytometer
(BD Biosciences). The following fluorescein isothiocyanate
(FITC) or phycoerythrin (PE) conjugated mouse anti-human
monoclonal antibodies were used for direct labeling of the
cells: antiCD1a-PE (clone BL6), antiCD14-FITC (RMO52),
both from Beckman-Coulter, Krefeld, Germany. Isotype
matched monoclonal antibodies of irrelevant specificity were
used as controls.
Allogenic mixed lymphocyte reaction
The T cell stimulatory capacity of monocyte derived dendritic
cells generated in the presence or absence of dust extract was
determined by measuring induction of interferon c (IFN-c)
in an allogenic mixed lymphocyte reaction. 16104 monocyte
derived dendritic cells were incubated with 16105 allogenic
lymphocytes in a 96-well flat bottom cell culture plate (Nunc,
Wiesbaden, Germany) for 96 hours in CTCM. Concentrations
of IFN-c were assessed in cell free supernatants by ELISA
(IFN-c OptEIA Set, BD Biosciences).
Statistical analysis
Statistical analysis was performed to test whether treatment
with dust extract leads to a significant reduction in several
parameters associated with allergic disease. For this purpose,
data from the mouse model were analysed by the two tailed
Mann-Whitney test. In vitro studies with human leucocytes
were analysed by the two tailed Wilcoxon matched pairs test.
Graph Pad Prism Software (Version 3.03) was used for
analysis. Values of p,0.05 were considered statistically
significant. All results are presented as median with 25–
75th percentile in parentheses.
RESULTS
Effect of treatment with stable dust extract on AHR
Following sensitisation and challenge with OVA, the mice
developed marked AHR compared with non-sensitised
controls (fig 2). To examine the influence of stable dust on
allergen induced AHR, mice were exposed to an aerosol of
dust extract during sensitisation and first challenge. Mice
treated with dust extract were nearly as unresponsive to
methacholine provocation as non-sensitised mice. In con-
trast, treatment of mice with a solution containing 0.8 mg/ml
E coli LPS as a matched control to the LPS content of dust
extract did not reduce AHR. Treatment of non-sensitised
mice with dust extract did not induce changes in airway
reactivity (data not shown).
Suppression of airway eosinophilia following
treatment with stable dust extract
In addition to AHR, allergic asthma is characterised by airway
inflammation with predominant infiltrates of eosinophils. As
shown in fig 3, the BAL fluid of non-sensitised mice
contained only moderate numbers of macrophages, no
lymphocytes, and no eosinophils. After sensitisation and
challenge with OVA, eosinophils (primarily) and also
lymphocytes and macrophages were recruited to the airways
to give BAL fluid levels of 9.66105 (7.6–11.56105) eosino-
phils and 16105 (0.8–1.16105) lymphocytes. Treatment of
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Figure 2 Airway responsiveness following exposure to stable dust
extract during sensitisation. Airway responsiveness to methacholine was
measured 24 hours after the second challenge with ovalbumin (OVA) in
mice treated by inhalation of dust extract (n = 16) or sham treated with
phosphate buffered saline (PBS; n = 16) during sensitisation. Another
control group was treated during sensitisation by inhalation of
lipopolysaccharide (LPS) as a matched control to LPS content of dust
extract (n = 8). Median Penh values from groups of mice were related to
the methacholine concentrations used for provocation. Whiskers
represent the 25–75th percentile of median values. ***p,0.001 dust
extract treated mice v PBS treated mice.
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Figure 3 Effect of exposure to stable dust extract on allergen induced
airway inflammation. Total number of eosinophils, lymphocytes and
macrophages in BAL fluid recovered from mice treated by inhalation of
dust extract (n = 16) or sham treated with phosphate buffered saline
(PBS, n = 16) during sensitisation were counted and differentiated to
evaluate recruitment of leucocytes to the airways. Another control group
was treated during sensitisation by inhalation of lipopolysaccharide
(LPS) as a matched control to the LPS content of dust extract (n = 8). Boxes
represent the 25–75th percentiles, horizontal lines represent median
values; whiskers show the highest and lowest values.
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mice with LPS did not have any significant effect on cell
recruitment to the airways induced by sensitisation and
challenge. In contrast, treatment with stable dust extract led
to a significant suppression of eosinophil and lymphocyte
recruitment to the airways, with BAL fluid levels of 0.46105
(0.2–0.76105) eosinophils and 0.36105 (0.2–0.76105) lympho-
cytes.
Influence of treatment with dust extract on production
of Th2 cytokines
Airway eosinophilia is dependent on the secretion of Th2 type
cytokines, especially IL-5, from Th2 lymphocytes as a
consequence of allergic sensitisation.15 Accordingly, sensitisa-
tion caused induction of Th2 cytokines with increased in vitro
production of IL-5 and IL-10 in splenocyte cultures re-
stimulated with OVA (table 1). However, in vitro production
of IL-5 by splenocytes from sensitised and dust treated mice
was reduced by about 63% compared with sensitised mice
sham treated with PBS. Treatment with LPS, however, did
not result in a significant reduction in sensitisation induced
IL-5 production but tended to increase IL-5 concentrations in
vitro. Production of IL-10 did not seem to be affected by
inhalation of dust extract.
Influence of stable dust extract on development of
humoral immune responses to allergens
Serum levels of OVA specific IgG1 and IgE antibodies
increased substantially after sensitisation (table 2).
Following treatment with dust extract during sensitisation,
the production of both OVA specific IgG1 and IgE was
reduced compared with mice sham treated with PBS during
sensitisation. Inhalation of LPS during sensitisation did not
have any significant effect on the production of either
antibody isotype. Interestingly, OVA specific IgG2a anti-
bodies, which are associated with Th1 responses and which
were only marginally but significantly increased in the serum
after sensitisation and challenge, did not increase in
concentration following treatment with dust extract.
Table 1 Effect of inhaled dust extract on IL-5 and IL-10
production of murine splenocytes
Treatment IL-5 (pg/ml) IL-10 (pg/ml)
PBS 834 (625.5–1002) 1459 (1164–1782)
LPS 1080 (806.5–1420) 1816 (1482–2030)
Dust extract 309 (248–402.3)
p,0.0001
1275 (842.8–1742)
p = 0.4398
Non-sensitised 5.2 (0–16.5) 91.5 (78–124)
IL, interleukin; PBS, phosphate buffered saline; LPS, lipopolysaccharide.
In vitro production of IL-5 and IL-10 was measured by ELISA after re-
stimulation of splenocytes with OVA for 2 days; n>8 per group. Results
are presented as median with 25–75th percentile in parentheses. Dust
extract treated mice were compared with PBS treated mice by the two
tailed Mann-Whitney test.
Table 2 Effect of inhaled dust extract on serum antibody production in mice
Treatment
IgE
(6105 U/ml)
IgG1
(6105 U/ml)
IgG2a
(OD405)
PBS 2.7 (1.7–5.6) 11.1 (8.1–19.6) 0.15 (0.13–0.27)
LPS 2.2 (1.3–5.6) 13.3 (8.4–26.7) 0.14 (0.13–0.3)
Dust extract 1.3 (0.9–2.0), p = 0.017 5.5 (2.0–8.1), p = 0.001 0.17 (0.13–0.2)
Non-sensitised 0 0 0.09
PBS, phosphate buffered saline; LPS, lipopolysaccharide.
Serum levels of OVA specific IgE, IgG1, IgG2a were measured by ELISA and expressed as arbitrary units; n >8 per
group. The results are presented as median with the 25–75th percentile in parentheses. Dust extract treated mice
were compared with PBS treated mice by the two tailed Mann-Whitney test.
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Figure 4 Effect of dust extract inhalation on allergen specific IgE levels
in the airways. BAL fluid was collected following sensitisation to OVA
and two OVA aerosol challenges. Concentrations of OVA specific IgE
antibodies were measured by ELISA. Individual values expressed as
arbitrary units and median values are shown. No OVA specific IgE was
detected in non-sensitised mice (data not shown).
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Figure 5 Surface expression of CD14 and CD1a on monocyte derived
dendritic cells. Peripheral blood monocytes from six donors were
cultured for 7 days with GM-CSF and IL-4 (G/I), GM-CSF/IL-4 and LPS
(G/I + LPS), or GM-CSF/IL-4 and dust extract (G/I + dust extract).
Resulting cells were evaluated by FACS for expression of (A) CD14 and
(B) CD1a. Boxes represent the 25–75th percentiles, horizontal lines
represent median values; whiskers show the highest and lowest values.
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To determine local antibody responses in the airways
during allergic inflammation, OVA specific IgE was also
measured in BAL fluid.16 IgE titres in sensitised and sham
treated mice were significantly higher than in non-sensitised
mice which did not have any detectable OVA specific
antibodies in BAL fluid. Inhalation of dust extract signifi-
cantly reduced IgE titres in BAL fluid (fig 4) while treatment
with LPS had no significant effect.
Reduced T cell stimulatory capacity of human
dendrit ic cells generated in the presence of stable dust
extract
Allergen induced airway inflammation and AHR are thought
to depend on T cell responses. T cells in turn require
activation by specialised antigen presenting dendritic cells.
To determine whether dendritic cell differentiation can be
inhibited by substances present in the dust extract, we tested
the influence of the extract on in vitro generation of
monocyte derived dendritic cells.
Monocytes isolated from human blood were cultured in the
presence of GM-CSF and IL-4 for 7 days resulting in dendritic
cell differentiation as demonstrated by expression of CD1a
and downregulation of CD14 (fig 5). The presence of 2 ng/ml
E coli LPS (concentration matched to LPS concentration in
dust extract) during culture did not seem to have an
influence on dendritic cell differentiation with respect to
upregulation of CD1a and downregulation of CD14. In
contrast, the presence of dust extract inhibited the GM-CSF
and IL-4 (G/I) induced differentiation of monocytes, reducing
upregulation of CD1a while partially maintaining CD14
expression. These incompletely differentiated cells had a
reduced T cell stimulatory capacity in allogenic mixed
lymphocyte reactions as measured by IFN-c release. In the
presence of cells differentiated with dust extract, IFN-c
production was significantly reduced by 37.1% compared
with IFN-c concentrations in mixed lymphocyte reactions
with monocyte derived dendritic cells generated in the
absence of dust extract (G/I = 7.0 ng/ml (5.5–32.9); G/I+
dust extract = 4.4 ng/ml (1.2–15.1); n = 6; p = 0.03).
Monocyte derived dendritic cells from matched LPS control
cultures did not significantly change IFN-c production in
mixed lymphocyte reactions (G/I+LPS = 6.6 ng/ml (5.4–
19.1), not significant (p = 0.16) versus G/I).
DISCUSSION
In this study we present evidence that dust collected from
stables of traditional farms contains biologically active factors
which, after extraction with physiological sodium chloride
solution and administration by inhalation, can protect mice
from allergic sensitisation, eosinophilic airway inflammation,
and resulting AHR. This is the first experimental approach to
confirm the epidemiological observation that exposure to the
stable environment of traditional farms reduces the risk of
allergic diseases.1–4
The method used in our study to extract substances from
stable dust is likely to be comparable to the natural situation
in the bronchial mucosa where salt containing mucosal fluid
probably extracts similar substances from inhaled stable dust
particles. The effect of dust extract inhalation was particu-
larly strong on AHR and airway inflammation, while the
protective activity of inhaled dust extract on systemic
sensitisation was less pronounced. Mean antibody titres
(IgG1 and IgE) in the serum of mice treated with dust extract
were only slightly reduced. This indicates that inhaled dust
extract mainly acts locally in the airways, inhibiting the
effects of airway allergen challenges and, to a lesser extent,
the systemic responses to intraperitoneal sensitisation with
OVA and aluminum hydroxide. This interpretation is further
supported by the observation that, in contrast to serum levels,
local concentrations of OVA specific IgE in BAL fluid were
markedly reduced after dust extract inhalation. These
findings indicate that the anti-allergic effects of dust extract
would be even more pronounced in a model of sensitisation
exclusively via the airways. Such a model may reflect allergen
sensitisation in infants more closely than intraperitoneal
hyperimmunisation used in this study.
Several authors have observed similar reductions in airway
symptoms after treatment with solutions of microbes or
microbial compounds. Broide et al showed that bacterial CpG-
oligodeoxynucleotides led to suppression of allergen induced
asthma in mice, and Hopfenspirger et al found that treatment
with mycobacterial antigens could attenuate allergen induced
airway eosinophilia and deterioration of lung function even
in mice with established allergic airway inflammation.7 8 11 17–19
Furthermore, there is a body of information regarding the
effects of LPS in mouse models of asthma which shows that
systemic treatment with LPS in relatively high doses results
in at least partial reduction of allergic symptoms.7 8 In all of
these experiments LPS seemed to induce a shift towards Th1
responses. This is in contrast to our findings of slight
enhancement of Th2 responses following LPS treatment
and a lack of Th1 response after inhalation of stable dust
extract. This difference may be due to the comparatively low
concentration of LPS in stable dust extract and the matched
LPS concentration used in our control experiments. It has
been shown previously that low concentrations of LPS are not
only unable to inhibit allergic sensitisation and Th2
responses, but that they can even enhance these.8 Although
the endotoxin concentration in dust extract is too low to
inhibit sensitisation of mice, we cannot exclude the
possibility that it acts synergistically with other immune
modulatory substances of farm dust as Roy et al20 have shown
for IL-10 and IL-12 release of human peripheral blood
mononuclear cells after stimulation with barn dust DNA in
vitro.
Considering the lack of a Th1 shift, it is likely that the
immune modulation induced by stable dust extract was
based on the induction of immunological tolerance or
suppression. This hypothesis is supported by our results
showing that human monocyte derived dendritic cells
generated in the presence of dust extract showed a much
weaker T cell stimulatory capacity than those generated
without dust extract. This lack of stimulatory capacity was
associated with persistent CD14 and reduced CD1a expres-
sion, indicating incomplete differentiation from monocytes
into dendritic cells in the presence of dust extract. The stable
dust extract may therefore exert an influence on allergic
immune responses by modulating differentiation and func-
tion of antigen presenting cells (APC). It is tempting to
speculate that modulation of APC differentiation by compo-
nents of stable dust may lead to unresponsiveness of allergen
specific T cells. Although we do not present direct evidence
for this hypothesis, our data indicate downregulation of the T
cell response rather than activation.
Finally, the finding that stable dust extract used in our
study contained immune modulatory substances which were
able to inhibit the development of allergic sensitisation,
eosinophilic airway inflammation, and changes in lung
function could lead the way to new prophylactic treatments
for the prevention of allergic diseases. In particular, the
observation that inhalation of stable dust extract resulted in
suppression or unresponsiveness rather than induction of
Th1 responses against the allergen makes stable dust derived
compounds interesting candidates for therapeutic approaches
in humans, since the lack of Th1 induction may reduce the
risk of undesirable side effects such as autoimmunity.21
In summary, we have established an experimental
schedule which will allow the identification of relevant
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biologically active compounds in the inhaled stable dust
extract. Using this experimental schedule, our study shows
that it is possible to extract highly active substances from
stable dust which can suppress sensitisation in a mouse
model of allergic asthma. The priority now is to define the
active factors in stable dust and to establish their precise
mode of action.
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